Glaxo Names Bailey to Replace Connelly Atop Ailing U.S. Unit
This article is for subscribers only.
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, promoted Jack Bailey to replace Deirdre Connelly as head of its struggling U.S. pharmaceutical operations.
Connelly, 54, will retire after six years as president for North America, London-based Glaxo said in a statement to its employees today. Bailey, who joined Glaxo in May 2009 and was most recently senior vice president for policy, payers and vaccines, will step into his new role immediately.